CN1220596A - 含有十六烷基氯化吡啶鎓和一种两性表面活性剂的漱口药组合物 - Google Patents
含有十六烷基氯化吡啶鎓和一种两性表面活性剂的漱口药组合物 Download PDFInfo
- Publication number
- CN1220596A CN1220596A CN97195116A CN97195116A CN1220596A CN 1220596 A CN1220596 A CN 1220596A CN 97195116 A CN97195116 A CN 97195116A CN 97195116 A CN97195116 A CN 97195116A CN 1220596 A CN1220596 A CN 1220596A
- Authority
- CN
- China
- Prior art keywords
- cpc
- mouth
- wash
- surfactant
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002324 mouth wash Substances 0.000 title claims abstract description 53
- 229940051866 mouthwash Drugs 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 239000002280 amphoteric surfactant Substances 0.000 title abstract description 5
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 title abstract description 4
- 229960001927 cetylpyridinium chloride Drugs 0.000 title abstract 2
- -1 amido propyl betaine Chemical compound 0.000 claims description 33
- 239000004094 surface-active agent Substances 0.000 claims description 25
- 241000737241 Cocos Species 0.000 claims description 22
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 22
- 125000003368 amide group Chemical group 0.000 claims description 22
- 210000000214 mouth Anatomy 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 claims description 4
- 235000012677 beetroot red Nutrition 0.000 claims description 4
- 239000001654 beetroot red Substances 0.000 claims description 4
- 235000002185 betanin Nutrition 0.000 claims description 4
- 239000003093 cationic surfactant Substances 0.000 claims description 3
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 1
- 229960003237 betaine Drugs 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 210000003298 dental enamel Anatomy 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 17
- 241000283690 Bos taurus Species 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000008367 deionised water Substances 0.000 description 10
- 229910021641 deionized water Inorganic materials 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 230000000717 retained effect Effects 0.000 description 8
- 239000011775 sodium fluoride Substances 0.000 description 8
- 235000013024 sodium fluoride Nutrition 0.000 description 8
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 7
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 7
- 239000008389 polyethoxylated castor oil Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 235000013599 spices Nutrition 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 229920013820 alkyl cellulose Polymers 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 206010006326 Breath odour Diseases 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 208000032139 Halitosis Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 210000004268 dentin Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- YUOWTJMRMWQJDA-UHFFFAOYSA-J tin(iv) fluoride Chemical compound [F-].[F-].[F-].[F-].[Sn+4] YUOWTJMRMWQJDA-UHFFFAOYSA-J 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical class OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002272 anti-calculus Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- MJQOAGGQHLETNJ-UHFFFAOYSA-N azepane;phosphono dihydrogen phosphate Chemical compound C1CCCNCC1.OP(O)(=O)OP(O)(O)=O MJQOAGGQHLETNJ-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- QNNOMMQTMSHMBN-UHFFFAOYSA-N calcium;2,3-dihydroxypropyl dihydrogen phosphate Chemical compound [Ca].OCC(O)COP(O)(O)=O QNNOMMQTMSHMBN-UHFFFAOYSA-N 0.000 description 1
- 239000004075 cariostatic agent Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229940091249 fluoride supplement Drugs 0.000 description 1
- SKSIDEOZXDVBGN-UHFFFAOYSA-N fluoro dihydrogen phosphate Chemical compound OP(O)(=O)OF SKSIDEOZXDVBGN-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 150000002461 imidazolidines Chemical class 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 235000010434 neohesperidine DC Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- RJQRCOMHVBLQIH-UHFFFAOYSA-M pentane-1-sulfonate Chemical compound CCCCCS([O-])(=O)=O RJQRCOMHVBLQIH-UHFFFAOYSA-M 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- RXSHXLOMRZJCLB-UHFFFAOYSA-L strontium;diacetate Chemical compound [Sr+2].CC([O-])=O.CC([O-])=O RXSHXLOMRZJCLB-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Detergent Compositions (AREA)
- Confectionery (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
Abstract
本发明涉及含有十六烷基氯化吡啶鎓和式(1)的酰氨基甜菜碱两性表面活性剂的漱口药组合物,式(1)是RC(O)NH(CH2)aN+(R1)(R2)(CH2)bCO2 -,其中R为C10-20的烷基,R1,R2各自为C1-4烷基,a为1到4的整数,b为1到4的整数。
Description
本发明涉及含有十六烷基氯化吡啶鎓(CPC)和一种两性表面活性剂的漱口药组合物。
在口腔卫生组合物中阳离子抗茵剂例如CPC已广泛用作一种降低噬茵斑的方法,也可用于预防和/或治疗口臭、牙周病、噬斑、结石和/或龋齿。
尽管含CPC的漱口药已被广泛使用,但它们存在如下缺点:由于其中存在的阴离子赋形剂降低了CPC的活性从而降低了效率。
虽然以前提倡非离子表面活性剂和阴离子抗茵剂一起使用,但现在发现许多这类表面活性剂会影响CPC漱口药的效果。
令人意外的是,现在发现特殊的两性酰氨基甜菜碱表面活性剂比非离子表面活性剂(例如聚乙氧基山梨醇酯,氧化乙烯缩聚物(聚氧乙烯)和聚乙氧基氢化蓖麻油)更能与CPC相容。
因此本发明提供了这样的一种漱口药组合物,它包含一种抑茵有效量的CPC、一种口腔可接受的载体或赋形剂、和一种具有如下分子式的酰氨基甜菜碱:
RC(O)NH(CH2)aN+(R1)(R2)(CH2)bCO2 -其中R为C10-20的烷基,优选C12-16烷基;
R1,R2各自为C1-4烷基,优选甲烷;
a为1到4的整数,优选3;以及
b为1到4的整数,优选1。
适合的酰氨基甜菜碱的例子包括:椰酰氨基乙基甜菜碱、椰酰氨基丙基甜菜碱或月桂酰氨基甜菜碱、或其混合物,优选椰酰氨基丙基甜菜碱,其在漱口药组成中与CPC特别相容。
适合的CPC含量为0.005到10%,优选0.01到5%,更优选0.02到2.5%(按漱口药重量比)。
酰氨基甜菜碱适合与另一种选自非离子、另一种两性或阳离子的表面活性剂或其混合物共存。
适合的非离子表面活性剂包括,例如聚乙氧基山梨醇酯,特别是聚乙氧基山梨醇单酯,如PEG(40)脱水山梨醇二异硬脂酸酯,和ICI供应的商品名为‘Tween’的产品;环氧乙烷和环氧丙烷的缩聚物(聚羟体),例如由BASF-Wyconlotte供应的商品名为‘Pluromc’的产品;丙二醇缩合物;聚乙氧基氢化蓖麻油,例如克列莫佛(Cremophor);和脱水山梨醇脂肪酯。
适合的另外的两性表面活性剂包括长链咪唑啉衍生物如由Miranol供应的商品名为‘Miranol C2M’的产品和长链烷基甜菜碱,例如由Albright+Wilson供应的商品名为‘Empigen BB’的产品及其混和物。
适合的阳离子表面活性剂包括乙基-N-可可-L-精氨酸的D,L-2-吡咯烷酮-5-羧酸盐,由Ajinomoto Co.Inc供应的商品名为CAE的产品;椰酰氨基丙基PG二甲基季铵氯化磷酸酯和月桂酰氨基PG二甲基季铵氯化磷酸酯,分别来自Mona公司的商品名为Monuquat PTC和Monaqunt PTL。
以酰氨基甜菜碱作为表面活性剂的合适含量为50-100%。
优选为65-90%的酰氨基甜菜碱。
更优选只用酰氨基甜菜碱一种表面活性剂。
在漱口药中合适的表面活性剂总含量为0.01-20%,优选0.05-10%,更优选0.1-5%。
合适的漱口药制剂有一种含水碱溶液或乙醇溶液,也可以还有另一种液体例如甘油或丙二醇。漱口药可以“随时可用”的形式提供;作为浓缩液的形式,使用者可在使用前将其稀释;或者以固体形式片剂或囊剂的形式提供,在使用前立即将其溶解。片剂可用木糖醇和/或山梨醇作主要成分制备。溶解后,囊剂和片剂可以作为无泡漱口药,或者加入一适当的发泡剂例如碳酸钠/碳酸氢钠和柠檬酸作为泡沫漱口药。
这种组合物会含有从传统口腔清洁组分中为此目的而选出的适当的配制试剂,例如吸湿剂,增稠剂、调味剂,增甜剂,色剂和防腐剂,这些添加剂可与CPC和上述表面活性剂配用。
合适的增稠剂包括非离子增稠剂比如(C1-6)烷基纤维素醚,例如:甲基纤维素;羟基(C1-6)烷基纤维素醚,例如羟乙烯基纤维素和羟丙基纤维素;(C2- 6)亚烷氧基修饰的(C1-6)烷基纤维素醚,例如羟丙基甲基纤维素;及其混合物。其它的增稠剂也可以使用,包括天然和人工合成的树胶或物质,例如:Irash Moss,西黄耆胶,羧甲基纤维素钠盐,聚乙烯吡咯烷酮,淀粉和增稠硅。
较适合的增稠剂含量范围按组合物重量计为0.01-30%,优选于0.1-15%,更优于1-5%。
适合用于本发明组合物中湿润剂包括例如甘油、山梨醇、丙二醇或聚乙二醇,或其混合物。该湿润剂用量为组合物重量的5-70%,优选5-30%,更优选10-30%。
本发明的这些组合物可进一步包括一种抗龋剂,例如氟离子源如碱金属或胺氟盐如氟化钠,氟化锡(Ⅱ)。另外,氟离子也可来源于单氟磷酸碱金属盐,例如单氟磷酸钠。可以与一种可增强单氟磷酸盐活性(GB 1384375Beecham Group)的试剂如磷酸甘油钙盐组合使用。合适的组合物氟离子浓度为50-2500ppm,优选100-1500ppm,最优选100-250ppm。
本发明的这种组合物也可包括其它的通常用于口腔卫生组合物的活性物质,例如:CPC外的另一种诸如氯已定或三氯生的抗噬茵剂;防牙垢剂,如四或二碱金属丙酮酸盐,或其混合物,碱金属三磷酸盐或氮杂环庚烷二磷酸盐;或抗灵敏性的药剂例如乙酸锶,氯化锶或硝酸钾、氯化钾、柠檬酸钾等钾盐。这些药剂可在起到所预期治疗效果的含量范围内,并可与CPC相容。
本发明漱口药组合物的PH值范围通常为PH4-10,可以为5.5~8,这些都是口腔可接受的。
本发明漱口药组合物的制备可以按任何方便的顺序将适当剂量的组分混合,并可将PH值调到最后要求的数值。
本发明还提供了用来消灭口腔细茵,预防或治疗口腔异味、牙周病、蚀斑、结石和/或龋齿的方法,该方法包括在口腔中使用本发明的组合物。
以下的实施例阐明了本发明。实施例1(非离子表面活性剂的使用)
由以下物质构成的漱口药:
%w/w
Cremophor RH60* 0.2
CPC 0.05
香料 0.12
乙醇 15.00
NaF 0.05
糖精 0.052
专利蓝-V-0.5% 0.075
叶绿酸 0.01
去离子水 84.443
*Cremophor RH60是一种在聚乙氧基链中平均60个乙氧基单位的聚乙氧基氢化蓖麻油。实施例2(非离子表面活性剂的使用)
由以下物质构成的漱口药:
%w/w
Cremophor RH60 0.2
CPC 0.05
香料 0.12
乙醇 8.00
NaF 0.023
糖精 0.04
NHDC(新橙皮苷DC) 3.00
专利蓝-V-0.5% 0.075
叶绿酸 0.01
去离子水 88.482实施例3(椰酰氨基丙基甜菜碱的使用)
由以下物质构成的漱口药:
%w/w
椰酰氨基丙基甜菜碱 0.2
CPC 0.05
香料 0.12
乙醇 15.00
NaF 0.05
糖精 0.052
专利蓝-V-0.5% 0.075
叶绿酸 0.01
去离子水 84.443实施例4(使用椰酰氨基丙基甜菜碱)
由以下物质构成的漱口药:
%w/w
椰酰氨基丙基甜菜碱 0.2
CPC 0.05
香料 0.12
乙醇 8.00
NaF 0.023
糖精 0.04
NHCD(新橙皮苷DC) 3.00
专利蓝-V-0.5% 0.075
叶绿酸 0.01
去离子水 88.482实施例5(使用椰酰氨基丙基甜菜碱)
由以下物质构成的漱口药:
%w/w
椰酰氨基丙基甜菜碱 0.65
CPC 0.05
香料 0.13
乙醇 15.00
NaF 0.05
糖精 0.06
专利蓝-V-0.5% 0.075
叶绿酸 0.01
去离子水 83.975实施例6(使用椰酰氨基丙基甜菜碱和非离子表面活性剂)
由以下物质构成的漱口药:
%w/w
椰酰氨基丙基甜菜碱 0.10
Cremophor RH60 0.05
CPC 0.05
香料 0.13
乙醇 15.00
NaF 0.05
糖精 0.06
专利蓝-V-0.5% 0.075
叶绿酸 0.01
去离子水 84.475实施例7(使用椰酰氨基丙基胺甜菜碱)
由以下物质构成的漱口药:
%w/w
椰酰氨基丙基甜菜碱 0.30
CPC 0.05
香料 0.13
乙醇 15.00
NaF 0.05
糖精 0.06
专利蓝-V-0.5% 0.075
叶绿酸 0.01
去离子水 84.475实施例8(牙釉质/羟基磷灰石复盘的体外研究)
已知表面积的羟基磷灰石(HA)复盘或牛牙釉质是通过将一条3英寸的棉线加在复盘上或牙齿的空根部管道中制备。对羟基磷灰石复盘棉线用指甲油固定,对于牛牙釉质则用乙烯基硅氧烷(如Reprosil)薄膜覆盖牙齿暴露的牙本质,这可以使棉线固定并掩盖暴露的牙本质,防止CPC结合这一位置。牙齿或HA复盘用后放入无茵的容器(1个容器一个牙齿),然后每个容器中加入5ml过滤后的全人唾液。牙齿在32℃保温过夜。次日每一牙齿均用去离子水(25ml)漂洗15秒,接着用CPC漱口药或简单溶液(10mol)处理一分钟。牙齿用去离子水漂洗3次(25ml),移去Reprosil和棉线,牙齿再在如下溶液中漂洗3分钟,以除去结合在牙齿/复盘上的CPC:50%乙腈,30%四氢呋喃,19.9%专离子水,0.1%的戊烷磺酸溶液。将溶液加入合适的HPLC管中分析CPC的含量。这可以提供结合详细信息。为得到对照结果,在牙齿用乙腈/四氢呋喃磺酸戊烷混合物漂洗前先在5ml过滤过的人唾液中37℃保温2小时,然后连续做结合实验。
通过检查在漱口药中的羟基磷灰石复盘结合的CPC对照在单溶液中的结合情况发现,大约60%的CPC结合能力丧失了:
实施例1漱口药:1.68mg/cm2 CPC结合到复盘
0.05%CPC简单水溶液:5.36mg/cm2的CPC结合复盘(n=5)
这表明漱口药中的赋形剂可降低CPC结合能力。因此我们可检查实施例1中的漱口药减去每一赋形剂以确定哪一种对CPC结合能力可能有最有害的作用。
实施例1中漱口药:1.62mg/cm2 CPC结合到复盘
实施例1中漱口药减CREMOPHOR RH60(溶剂):2.611ug/cm2CPC结合到复盘(n=5)。
我们也检查了仅含一种赋形剂的简单CPC溶液(0.05%)也确定哪一个有有害的作用。
0.05%CPC简单水溶液有5.52mg/cm2 CPC结合到复盘
0.05%CPC+Cremophor RH60,2.36mg/cm2结合到复盘(n=5)
加溶剂Crephophor RH60,被认为是对降低CPC结合能力起主要作用的赋形剂。
检查了不同的加溶剂,以确定CPC的结合/保留牛釉质的情况,这些加溶剂是Tween 80,Tween 20,phnronic F127,Plnromic F108.Cremophor RH40,Cremophor Rh60,对它们在实施例1漱口药中不同用量作了检查,但它们都不如CremophorRH60,0.2%(n=10)
接着对另一加溶剂Tegobetoin(椰酰氨基丙基甜菜碱)的不同用量水平(0.2%,0.4%1%)相对于实施例1的漱口药中Cremophor 60(0.2%)作了检查:
实施例3漱口药:1.44ug/cm2CPC保留在牛釉质上
实施例1漱口药:0.60ug/cm2CPC保留在牛釉质上
通过使用0.02%的椰酰氨基丙基甜菜碱表面活性剂,可显著提高CPC在牛釉质上的保留能力,得到了令人鼓舞的结果。
对改性的制剂作了进一步研究,得到了如下的结果:
实施例2中漱口药:0.58ug/cm2CPC保留在牛釉质上
实施例4中漱口药:0.93ug/cm2CPC保留在牛釉质上
实施例2中漱口药:1.23umg/cm2CPC结合在牛釉质上
实施例4中漱口药:2.54mg/cm2CPC结合在牛釉质上
这些结果证明椰酰氨基丙基甜菜碱比非离子表面活性剂能很好地与CPC相容,总体上提高了CPC在牛釉质上的结合和保留能力。
另一项研究表明高含量椰酰氨基丙基甜菜碱有相似的优点,
实施例5中漱口药:0.95ug/cm2CPC保留在牛釉质上
实施例1中漱口药:0.68ug/cm2CPC保留在牛釉质上
对混合加溶剂系统做两个进一步的研究,结果如下:
实施例6中漱口药:2.56ug/cm2CPC结合在牛釉质上
实施例1中漱口药:1.62ug/cm2CPC结合在牛釉质上
实施例6中漱口药:1.15ug/cm2CPC保留在牛釉质上
实施例1中漱口药:0.68ug/cm2CPC保留在牛釉质上
得到的结果表明,在与仅含非离子表面活性剂如Cremophor RH60的漱口药制剂比较时,一种两性酰氨基甜菜碱表面活性剂或单独或与另一表面活性剂混合均提高了CPC在牛釉质上的结合和保留能力。实施例9(粘膜细胞的体外研究)
人的口腔颊上皮细胞用聚丙烯刮勺收集,转入贮存在冰中的20ml的静止唾液盐(RSS)缓冲液(50mM氯化钠,1.1mM氯化钙,0.6mM磷酸二氢钾)中。细胞通过在20ml RSS缓冲液中离心洗三次,以每管1ml的终浓度再悬浮在RSS缓冲液中。留着的细胞团以超声振动方法打破,然后用血细胞计数器计数。
实施例1和6的漱口药和细胞悬液在保温箱中37℃保温。然后将细胞悬液加入(0.5ml每份)玻璃试管中,离心,弃上清。然后加入0.5ml漱口药到细胞沉淀中,轻轻振荡使细胞在漱口药中悬浮,然后在37℃培养,轻轻摇动。
离心五分钟收集细胞。收集的细胞粒子用2ml RSS缓冲液洗3次。将1.5mlCPC移动相(50%乙腈,30%四氢呋喃,20%的水和0.1%的磺酸基戊烷)加到各沉淀粒子中,搅拌混匀,静置5分钟。离心,用HPLC分析上清液中的CPC,得到如下结果
实施例1中漱口药:6.07ugCPC结合/100000细胞
实施例6中漱口药:9.57ugCPC结合/100000细胞
这些结果证明与不含酰氨基甜菜碱的相似产品比较,酰氨基甜菜碱表面活性剂与另一种表面活性剂合用可显著提高CPC结合粘膜细胞的能力。实施例10(微生物保留结果)
羟基磷灰石复盘在唾液中浸泡后包被了细胞表膜,这些复盘在测试溶液中浸2分钟随即用去离子水洗两次。检测测试溶液的原液和1∶5稀释液。然后将复盘放在表面有Propionobacter acnes(痤疮丙酸杆菌)的琼脂平板培养基上,琼脂是脑心浸液琼脂,平板在37℃厌氧培养2天。检测抑制斑以确定复盘上保留CPC的微生物活性。
实施例1的漱口药,1∶5稀释液有18.65个抑制斑,原液有21.08个
实施例6的漱口药,1∶5稀释液有20.11个抑制斑,原液有23.58个
不含CPC,而含有椰酰氨基丙基甜菜碱的漱口药原液或1∶5稀释液不表现活性;0.05%/CPC溶液,1∶5稀释液可有20.98个抑制斑,原液有24.83个。
所得结果表明与另一表面活性剂共同使用的酰氨基甜菜碱表面活性剂可提高CPC在羟基磷灰石复盘上的保留能力,并且保留的CPC有微生物活性。这些结果与实施例8中的釉质和羟基磷灰石复盘中的结合和保留的研究结果是相一致的。实施例11(微生物活性)
膜电位敏感性变化的机理提供了检测细胞存活的方法。细菌中,能量代谢的细胞器位于细胞质内膜上。当细胞膜被物理或化学试剂扰乱时,膜电位降低,细胞死亡。使用流动细胞计量仪用荧光探针可以检测细菌存活力。其中双-(1,3-二丁基巴比土酸)三次甲基氧鎓醇(DiBAC4(3))最灵敏最耐用。它也适用于高效的流动细胞计量分析。带负电荷的氧鎓醇染料在细胞质和细胞外膜之间产生电位依赖性分布,并进入去极化(即死亡)的细胞中与脂类富集成分结合,由于积累而增加荧光度。
CPC是阳离子季铵化合物,其作用于细胞膜,造成功能丧失。这种功能丧失反映了摄入氧鎓醇(DiBAC4(3))量增加,从而增加意味着的细胞死亡的荧光度。由于漱口药应用技术中CPC是主要活性物质,因此决定用氧鎓醇和Biorad Bryte流动细胞计数器测定其抗变异链球茵的相对效力。测定按如下步骤进行:
实施例1,7中的漱口药各100ul和CPC+酰氨基甜菜碱对照物分别加入到每毫升含有约107个变异链球茵NCTC10904的2mlPBS缓冲液中。各加10ul lmg/ml的氧鎓醇溶液。20分钟后用Biorad Bryte流动细胞计数器测定荧光变化。对3个测试溶液中的每一个,均做平均荧光通道数(激发470-495/发射520-550nm)对时间的散点图。
图1曲线显示,相对于实施例1中漱口药,实施例7中漱口药中变异链球茵荧光强度更大。这表明含有酰氨基甜菜碱的制剂要比不含的对变异链球茵有机体有更大的损害(P<0.05)。
这些结果进一步确证了酰氨基甜菜碱的优点。
Claims (9)
1.一种漱口药组合物,含一种抑茵有效量的CPC;一种口腔可接受中的载体或赋形剂和一种具有如下分子式的酰氨基甜菜碱:
RC(O)NH(CH2)aN+(R1)(R2)(CH2)bCO2 -
其中R为C10-20的烷基;
R1,R2各自为C1-4烷基;
a为1到4的整数;以及
b为1到4的整数。
2.权利要求1中的组合物,其中酰氨基甜菜碱选自椰酰氨基乙基甜菜碱,椰酰氨基丙基甜菜碱成十二酰氨基甜菜碱,或其混和物。
3.权利要求2中的组合物,其中酰氨基甜菜碱为椰酰氨基丙基甜菜碱。
4.权利要求1到3中任一项的组合物,其中CPC的存在量为漱口药重量的0.005-10%。
5.权利要求1到4中任一项的组合物,其中酰氨基甜菜碱与另一种选自非离子、另一种两性或阳离子表面活性剂、或其混和物的表面活性剂共存。
6.权利要求5中的组合物,其中表面活性剂的50-100%为酰氨基甜菜碱。
7.权利要求5中的组合物,其中表面活性剂的65-90%为酰氨基甜菜碱。
8.权利要求1到4中任一项的组合物,其中酰氨基甜菜碱作为单一表面活性剂。
9.权利要求1到8中任一项的组合物,其中表面活性剂总量为漱口药重量的0.01-20%。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9611364.2A GB9611364D0 (en) | 1996-05-31 | 1996-05-31 | Composition |
GB9611364.2 | 1996-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1220596A true CN1220596A (zh) | 1999-06-23 |
Family
ID=10794565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97195116A Pending CN1220596A (zh) | 1996-05-31 | 1997-05-20 | 含有十六烷基氯化吡啶鎓和一种两性表面活性剂的漱口药组合物 |
Country Status (23)
Country | Link |
---|---|
US (1) | US6117417A (zh) |
EP (1) | EP0910333B1 (zh) |
JP (1) | JP2000511542A (zh) |
KR (1) | KR20000016215A (zh) |
CN (1) | CN1220596A (zh) |
AT (1) | ATE213618T1 (zh) |
AU (1) | AU706387B2 (zh) |
BR (1) | BR9709512A (zh) |
CA (1) | CA2256542C (zh) |
CZ (1) | CZ391398A3 (zh) |
DE (1) | DE69710726T2 (zh) |
DK (1) | DK0910333T3 (zh) |
EA (1) | EA001234B1 (zh) |
ES (1) | ES2173447T3 (zh) |
GB (1) | GB9611364D0 (zh) |
HK (1) | HK1019302A1 (zh) |
NZ (1) | NZ332781A (zh) |
PL (1) | PL330190A1 (zh) |
PT (1) | PT910333E (zh) |
TW (1) | TW467749B (zh) |
UA (1) | UA50766C2 (zh) |
WO (1) | WO1997046217A1 (zh) |
ZA (1) | ZA974713B (zh) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6471948B1 (en) * | 2000-03-22 | 2002-10-29 | Church & Dwight Co. Inc. | Toothpaste compositions containing cetylpyridinium chloride |
US8283135B2 (en) * | 2000-06-30 | 2012-10-09 | The Procter & Gamble Company | Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
US6355229B1 (en) | 2001-06-27 | 2002-03-12 | Church & Dwight Co., Inc. | Oral composition containing cetylpyridinium chloride and guar hydroxypropyltrimonium chloride and method of using the same |
US6579513B1 (en) | 2002-01-03 | 2003-06-17 | Playtex Products, Inc. | Hygiene mouthspray composition |
ES2657741T3 (es) * | 2002-06-07 | 2018-03-06 | Sunstar Inc. | Composición para la cavidad oral |
WO2004076632A2 (en) * | 2003-02-21 | 2004-09-10 | The Queen's Medical Center | Methods of screening for trpm5 modulators |
US9241885B2 (en) * | 2004-01-29 | 2016-01-26 | The Procter & Gamble Company | Oral care compositions comprising increased bioavailable levels of quaternary ammonium antimicrobials |
US7534816B2 (en) | 2005-07-01 | 2009-05-19 | Galaxy Surfactants Limited | Amidobetaines for oral care applications |
US20080299182A1 (en) * | 2007-03-01 | 2008-12-04 | Shuyuan Zhang | Methods and formulations for topical gene therapy |
WO2008155120A2 (en) * | 2007-06-20 | 2008-12-24 | Actogenix Nv | Methods and compositions for treating mucositis |
ME01256B (me) * | 2008-07-21 | 2013-06-20 | Dr Falk Pharma Gmbh | Farmaceutska formulacija za lečenje gornjeg digestivnog trakta |
DE102009054782A1 (de) | 2009-12-16 | 2011-06-22 | Henkel AG & Co. KGaA, 40589 | Mund- und Zahnpflege- und -reinigungsmittel mit Alkylpyridiniumsalzen I |
DE102009054781A1 (de) | 2009-12-16 | 2011-06-22 | Henkel AG & Co. KGaA, 40589 | Mund- und Zahnpflege- und -reinigungsmittel mit Alkylpyridiniumsalzen II |
JP5197707B2 (ja) * | 2010-10-07 | 2013-05-15 | サンスター株式会社 | 抗内毒素剤、及びこれを含有する歯周病抑制用口腔用組成物 |
US8933173B2 (en) | 2010-11-23 | 2015-01-13 | Chung Yuan Christian University | Surface anti-biomolecule agent |
US8980232B2 (en) | 2010-11-23 | 2015-03-17 | Chung Yuan Christian University | Dental care product |
US9675542B2 (en) * | 2011-05-16 | 2017-06-13 | Colgate-Palmolive Company | Oral care compositions |
JP6175428B2 (ja) | 2011-06-01 | 2017-08-02 | イントレクソン・アクトバイオテイクス・エヌブイIntrexon Actobiotics NV | 細菌のポリシストロン性発現系 |
AU2012289995B2 (en) * | 2011-08-02 | 2015-08-27 | The Procter & Gamble Company | Process for surfactant taste and/or odor improvement |
WO2013052958A2 (en) * | 2011-10-08 | 2013-04-11 | Microbial Defense Systems, Llc | Antimicrobial compositions and methods employing same |
GB201121300D0 (en) * | 2011-12-12 | 2012-01-25 | Glaxo Group Ltd | Novel composition |
US20150164778A1 (en) * | 2013-12-18 | 2015-06-18 | Honorio OBIAS | Pre-mix and process for preparing personal care compositions, composition promoting improved and long-lasting cleansing sensory experience, improved oral care composition |
EP3090728B1 (en) | 2013-12-27 | 2019-04-17 | Kao Corporation | Oral composition |
JP2017078029A (ja) * | 2015-10-19 | 2017-04-27 | アース製薬株式会社 | 殺菌方法及び殺菌組成物 |
WO2017122180A1 (en) | 2016-01-14 | 2017-07-20 | Intrexon Actobiotics N.V. | Compositions and methods for the treatment of type 1 diabetes |
WO2018031357A1 (en) | 2016-08-11 | 2018-02-15 | Colgate-Palmolive Company | Oral care compositions |
CN109843320A (zh) | 2016-09-02 | 2019-06-04 | 英特瑞克斯顿阿克图比奥帝克斯有限公司 | 稳定表达il-10和胰岛素的遗传修饰的细菌 |
CA3035488A1 (en) | 2016-09-13 | 2018-03-22 | Intrexon Actobiotics N.V. | Mucoadhesive microorganism |
US20220340621A1 (en) | 2019-09-27 | 2022-10-27 | Intrexon Actobiotics Nv D/B/A Precigen Actobio | Treatment of celiac disease |
WO2021167845A1 (en) * | 2020-02-18 | 2021-08-26 | Sunstar Americas, Inc. | Oral care composition |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2442712A1 (de) * | 1973-07-27 | 1976-03-25 | Blendax Werke Schneider Co | Mittel zur pflege und reinigung von zaehnen und zahnprothesen |
US4693888A (en) * | 1983-08-11 | 1987-09-15 | Lion Corporation | Caries-preventive composition |
WO1990015592A1 (en) * | 1989-06-12 | 1990-12-27 | Patrick John Shanahan | Anti-plaque dentifrice |
JPH0338516A (ja) * | 1989-07-05 | 1991-02-19 | Shiseido Co Ltd | 口腔用組成物 |
EP0408174A1 (en) * | 1989-07-12 | 1991-01-16 | Warner-Lambert Company | Antiseptic composition containing hexahydro-5-pyrimidinamine compounds |
JPH0684294B2 (ja) * | 1990-05-29 | 1994-10-26 | サンスター株式会社 | 口腔用組成物 |
JP3203534B2 (ja) * | 1993-11-11 | 2001-08-27 | 味の素株式会社 | 洗浄剤組成物 |
US5560905A (en) * | 1994-05-13 | 1996-10-01 | The Proctor & Gamble Company | Oral compositions |
-
1996
- 1996-05-31 GB GBGB9611364.2A patent/GB9611364D0/en active Pending
-
1997
- 1997-05-20 DE DE69710726T patent/DE69710726T2/de not_active Expired - Lifetime
- 1997-05-20 US US09/194,531 patent/US6117417A/en not_active Expired - Lifetime
- 1997-05-20 DK DK97924017T patent/DK0910333T3/da active
- 1997-05-20 BR BR9709512A patent/BR9709512A/pt not_active Application Discontinuation
- 1997-05-20 EA EA199800960A patent/EA001234B1/ru not_active IP Right Cessation
- 1997-05-20 CN CN97195116A patent/CN1220596A/zh active Pending
- 1997-05-20 KR KR1019980709784A patent/KR20000016215A/ko not_active Application Discontinuation
- 1997-05-20 UA UA98115887A patent/UA50766C2/uk unknown
- 1997-05-20 CZ CZ983913A patent/CZ391398A3/cs unknown
- 1997-05-20 EP EP97924017A patent/EP0910333B1/en not_active Expired - Lifetime
- 1997-05-20 CA CA002256542A patent/CA2256542C/en not_active Expired - Lifetime
- 1997-05-20 ES ES97924017T patent/ES2173447T3/es not_active Expired - Lifetime
- 1997-05-20 NZ NZ332781A patent/NZ332781A/xx not_active IP Right Cessation
- 1997-05-20 AU AU29619/97A patent/AU706387B2/en not_active Expired
- 1997-05-20 AT AT97924017T patent/ATE213618T1/de active
- 1997-05-20 PL PL97330190A patent/PL330190A1/xx unknown
- 1997-05-20 WO PCT/EP1997/002714 patent/WO1997046217A1/en not_active Application Discontinuation
- 1997-05-20 PT PT97924017T patent/PT910333E/pt unknown
- 1997-05-20 JP JP10500179A patent/JP2000511542A/ja active Pending
- 1997-05-29 ZA ZA9704713A patent/ZA974713B/xx unknown
- 1997-05-29 TW TW086107331A patent/TW467749B/zh not_active IP Right Cessation
-
1999
- 1999-06-08 HK HK99102552A patent/HK1019302A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2256542C (en) | 2008-08-19 |
HK1019302A1 (en) | 2000-02-03 |
KR20000016215A (ko) | 2000-03-25 |
EA199800960A1 (ru) | 1999-06-24 |
JP2000511542A (ja) | 2000-09-05 |
EA001234B1 (ru) | 2000-12-25 |
AU706387B2 (en) | 1999-06-17 |
PT910333E (pt) | 2002-08-30 |
ZA974713B (en) | 1998-05-12 |
CA2256542A1 (en) | 1997-12-11 |
WO1997046217A1 (en) | 1997-12-11 |
TW467749B (en) | 2001-12-11 |
PL330190A1 (en) | 1999-04-26 |
NZ332781A (en) | 2000-05-26 |
GB9611364D0 (en) | 1996-08-07 |
DK0910333T3 (da) | 2002-06-24 |
EP0910333A1 (en) | 1999-04-28 |
DE69710726T2 (de) | 2002-11-21 |
CZ391398A3 (cs) | 1999-05-12 |
ES2173447T3 (es) | 2002-10-16 |
AU2961997A (en) | 1998-01-05 |
ATE213618T1 (de) | 2002-03-15 |
US6117417A (en) | 2000-09-12 |
DE69710726D1 (de) | 2002-04-04 |
EP0910333B1 (en) | 2002-02-27 |
UA50766C2 (uk) | 2002-11-15 |
BR9709512A (pt) | 1999-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1220596A (zh) | 含有十六烷基氯化吡啶鎓和一种两性表面活性剂的漱口药组合物 | |
RU2493816C2 (ru) | Способы и комплекты для ухода за полостью рта | |
CN1102379C (zh) | 牙齿脱敏用可分散微粒系统 | |
CN1652744A (zh) | 包含二羧基官能化聚有机硅氧烷的口腔护理组合物 | |
CN1744873A (zh) | 稳定的包含亚氯酸盐的口腔护理组合物 | |
US20100297198A1 (en) | Liquid-type dentifrice composition contained silver particles and mousse-type dentifrice using the same | |
CN1085074A (zh) | 无刺激性洁牙用品 | |
AU2003237228A1 (en) | Liquid tooth whitening composition | |
JP2021516246A (ja) | 歯肉健康を促進するための口腔ケア組成物 | |
CN1200264A (zh) | 水性化妆品组合物以及使尿酸稳定溶于其中的方法 | |
CN1183268A (zh) | 洗涤剂组合物 | |
RU2526906C2 (ru) | Неводные однотубные композиции отбеливающего средства чистки зубов, способы их использования и получения | |
CN1036831C (zh) | 口腔保健用稳定的氟化亚锡组合物 | |
CN1822810A (zh) | 口腔用组合物 | |
CN1126432A (zh) | 用于治疗牙斑和牙龈炎的含有非阳离子型杀菌剂和碳酸氢盐的口用组合物 | |
JP2011153138A (ja) | 口腔用組成物 | |
JP2018039786A (ja) | 口腔用組成物及び口腔内歯垢分散剤 | |
AU623283B2 (en) | Oral rinse and method for plaque removal | |
CN85109275A (zh) | 口腔内用混合剂 | |
CN1191812C (zh) | 具有改进的牙齿增白作用的口腔用组合物 | |
CN1245985C (zh) | 含有抗坏血酸磷酸酯的组合物 | |
CN1812762A (zh) | 稳定的洁齿剂组合物 | |
Mani | Evidence-based clinical recommendations for fluoride use: a review | |
CN1065591A (zh) | 化妆品组合物 | |
US10076481B2 (en) | Compositions for treating periodontitis and dental calculus accumulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |